Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic and Wegovy.

In 2023, sales from Novo Nordisk's GLP-1 diabetes therapies grew 52% year over year. Ozempic and a sibling treatment called Rybelsus are to thank for that growth.

The drugmaker is a large and consistent client for Covington. The law firm has represented Novo Nordisk in several dozen ...

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...

Novo Nordisk (NVO) CEO Lars Fruergaard Jørgensen will step down after eight years at the helm of the Danish pharmaceutical giant responsible for the blockbuster drugs Ozempic and Wegovy, the ...

Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa ...

Novo Nordisk, the maker of popular drugs used for weight loss including Ozempic and Wegovy, says it is investing over $6 billion dollars to help meet the increased demand for the drugs amid ...

Novo Nordisk said it is pursuing multiple avenues to "protect patients from knockoff 'semaglutide' drugs" including litigation. Semaglutide is the active ingredient found in Wegovy and Ozempic.

The Food and Drug Administration on Tuesday approved Novo Nordisk 's Ozempic to treat chronic kidney disease in patients who also have Type 2 diabetes, expanding the use of the wildly popular ...

LONDON, May 2 (Reuters) – Novo Nordisk has seen the price of its hugely popular weight-loss drug Wegovy and diabetes drug Ozempic fall in the United States as volumes and competition have ...

Sept 2 (Reuters) - Novo Nordisk (NOVOb.CO) said the shortage of lower strengths of its diabetes drug Ozempic has deteriorated, with intermittent shortages for all strengths expected into the final ...